Trials / Unknown
UnknownNCT04951141
Clinical Study of Intratumoral Injection of CAR-T Cells in the Treatment of Advanced Liver Tumors
Beijing Immunochina Medical Science & Technology Co., Ltd.
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 69 Years
- Healthy volunteers
- Not accepted
Summary
Objective to study the safety and preliminary efficacy of intratumoral injection of CAR-T cells in the treatment of advanced liver tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | anti-GPC3 CAR-T cells | A single arm, open-label pilot study is designed to determine the safety and efficacy of anti-GPC3 CAR-T cells in patients with GPC3-positive advanced liver cancer. |
Timeline
- Start date
- 2019-01-01
- Primary completion
- 2023-09-30
- Completion
- 2023-12-21
- First posted
- 2021-07-06
- Last updated
- 2021-07-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04951141. Inclusion in this directory is not an endorsement.